广西医学2018，Vol.40Issue(10)：1175-1178,4.DOI:10.11675/j.issn.0253-4304.2018.10.17
不同方案治疗人表皮生长因子受体2阳性乳腺癌患者的临床效果比较
Clinical efficacy of different therapeutic regimens for breast cancer patients with human epidermal growth factor receptor 2-positive:a comparative study
康助习 1权瑞泉 1李洪波 1匡黎1
作者信息
- 1. 湖北医药学院附属东风医院肿瘤科,十堰市 442008
- 折叠
摘要
Abstract
Objective To compare the clinical efficacy among different therapeutic regimens for breast cancer patients with human epidermal growth factor receptor 2(HER2)-positive. Methods A total of 98 patients with breast cancer were divided into group A(32 cases),group B(34 cases) and group C(32 cases) using the random number table method. Group A was given docetaxel,cyclophosphamide and epirubicin,group B was treated with trastuzumab and carboplatin,and group C received paclitaxel,trastuzumab and carboplatin. The treatment lasted for 6 cycles in all groups. The objective response rate(ORR),clinical benefit rate(CBR),HER2 expression,median survival,and incidence of adverse reactions were compared among the three groups. Results After treatment,ORR and CBR in group C were higher than those in group A or B(P<0. 05);the rate of HER2-negaive in group B or C was higher than that in group A(P<0. 05);the median overall survival increased in sequence of group A<group B<group C(P<0. 05);no statistically significant difference was found in the incidence rate of adverse reactions among the three groups(P>0. 05). Conclusion Compared to chemotherapy drugs alone, targeted therapy combined with trastuzumab has favorable effects on breast cancer patients with HER2-positive and can significantly prolong survival time. Moreover,trastuzumab combine with docetaxel has better efficacy.关键词
乳腺癌/人表皮生长因子2/曲妥珠单抗/紫杉醇/多西他赛/卡铂Key words
Breast Cancer/Human epidermal growth factor receptor 2/Trastuzumab/Paclitaxel/Docetaxel/Carboplatin分类
医药卫生引用本文复制引用
康助习,权瑞泉,李洪波,匡黎..不同方案治疗人表皮生长因子受体2阳性乳腺癌患者的临床效果比较[J].广西医学,2018,40(10):1175-1178,4.
